Risk factors for in-hospital mortality in laboratory-confirmed COVID-19 patients in the Netherlands: A competing risk survival analysis.

Citation metadata

From: PLoS ONE(Vol. 16, Issue 3)
Publisher: Public Library of Science
Document Type: Report
Length: 5,493 words
Lexile Measure: 1520L

Document controls

Main content

Abstract :

Background To date, survival data on risk factors for COVID-19 mortality in western Europe is limited, and none of the published survival studies have used a competing risk approach. This study aims to identify risk factors for in-hospital mortality in COVID-19 patients in the Netherlands, considering recovery as a competing risk. Methods In this observational multicenter cohort study we included adults with PCR-confirmed SARS-CoV-2 infection that were admitted to one of five hospitals in the Netherlands (March to May 2020). We performed a competing risk survival analysis, presenting cause-specific hazard ratios (HR.sub.CS) for the effect of preselected factors on the absolute risk of death and recovery. Results 1,006 patients were included (63.9% male; median age 69 years, IQR: 58-77). Patients were hospitalized for a median duration of 6 days (IQR: 3-13); 243 (24.6%) of them died, 689 (69.9%) recovered, and 74 (7.4%) were censored. Patients with higher age (HR.sub.CS 1.10, 95% CI 1.08-1.12), immunocompromised state (HR.sub.CS 1.46, 95% CI 1.08-1.98), who used anticoagulants or antiplatelet medication (HR.sub.CS 1.38, 95% CI 1.01-1.88), with higher modified early warning score (MEWS) (HR.sub.CS 1.09, 95% CI 1.01-1.18), and higher blood LDH at time of admission (HR.sub.CS 6.68, 95% CI 1.95-22.8) had increased risk of death, whereas fever (HR.sub.CS 0.70, 95% CI 0.52-0.95) decreased risk of death. We found no increased mortality risk in male patients, high BMI or diabetes. Conclusion Our competing risk survival analysis confirms specific risk factors for COVID-19 mortality in a the Netherlands, which can be used for prediction research, more intense in-hospital monitoring or prioritizing particular patients for new treatments or vaccination.

Source Citation

Source Citation   

Gale Document Number: GALE|A656418639